辉瑞从 Seagen 收购的首个新型 ADC 未能通过 3 期 NSCLC 试验 - Fierce Biotech

Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial - Fierce Biotech

Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial Fierce Biotech Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC OncLive Pfizer drug acquired in Seagen deal disappoints in lung cancer study BioPharma Dive Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial CancerNetwork Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle? Kalkine Media

这条新闻具备可验证事件线索，可继续观察是否形成 Yes/No 预测问题。

同主题新闻会帮助 Google 识别事件簇，也让用户继续进入可交易话题。